|
Found 23 result(s) FROM 1963 pages containing the term 'vaccine'.
Friday Apr 09, 2010
Vaccine Successfully Reverse Type 1 Diabetes in Mice
Researchers believe the vaccine may be applicable to other autoimmune disease, such as RA and MS...
Monday Oct 19, 2009
Denosumab Approval Faces Delay
FDA-watchers predict that the agency will miss the October 19th target set for denosumab approval by as much as 3 months...
Wednesday Oct 07, 2009
Can Surgical Masks Protect You From Flu? Maybe
Surgical masks are nearly as effective as N95 respirators in preventing influenza in health care workers...
Wednesday Sep 30, 2009
FDA Finally OKs Stelara for Psoriasis
The FDA has approved Centocor's Stelara (ustekinumab) for moderate to severe psoriasis...
Monday Sep 21, 2009
RA Gene Screening Almost Ready for Primetime
Genetic screening for rheumatoid arthritis risk is not yet clinically useful, but combining five confirmed RA loci may provide an accurate predictive test...
Tuesday Feb 17, 2009
Some TNF Inhibitors Raise Shingles Risk in RA. Time to Vaccinate?
Anti-TNF monoclonal antibody drugs (adalimumab, infliximab) significantly increase herpes zoster risk in RA patients, and vaccination should be considered. Etanercept was not associated with increased herpes zoster risk...
Tuesday Nov 04, 2008
Genentech, Biogen Idec Rituxan Phase III Data in RA Patients Showed Patients who Received Fixed Interval Re-Treatment Maintained Treatment Response; Positive Phase III Data Also Reported for Rituxan plus MTX in Biologic-Naïve RA Patients, Immune Response in Rituxan-Treated Patients Yielded Mixed Results in Phase II Study
Rituxan, in combination with MTX, is indicated to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies...
Friday Aug 22, 2008
While Olympians Chase Medals, Chicken Collagen Advances as RA Immunotherapy
Inducing oral tolerance with chicken type II collagen (CCII) may help alleviate the signs and symptoms of rheumatoid arthritis (RA) with fewer side effects than methotrexate (MTX), Chinese researchers say…
Tuesday Jul 29, 2008
CEL-SCI Announces Positive Preclinical Results Using CEL-2000, a Chimeric Peptide with Bi-Functional Properties, as RA Vaccine
CEL-SCI Corp announced the discovery of CEL-2000, a novel peptide vaccine for the treatment of RA. Tests showed that CEL-2000 is equivalent or possibly superior to Enbrel® in slowing disease progression and lessening symptoms in mice...
Friday Feb 22, 2008
EUSA Out-Licenses Preclinical Stage Human Anti-IL-6 Antibody to GSK for up to $44 Million Plus Royalties
EUSA Pharma Inc announced that it has out-licensed the exclusive worldwide rights to its preclinical-stage human anti-interleukin (IL)-6 antibody (OP-R003) to GlaxoSmithKline (GSK)...
Tuesday Nov 06, 2007
Flu Shots Work for Patients on TNF-Inhibitors
TNF inhibitors reduce response to influenza vaccination, but about 80% of RA patients still develop protective titers after a single vaccine dose...
Wednesday Oct 31, 2007
Coley Initiates Phase I Study of First-in-Class TLR Antagonist, CPG 52364, for the Treatment of Systemic Lupus Erythematosus
Coley Pharmaceutical Group, Inc, an international biopharmaceutical company having a pipeline of Toll-Like Receptor (TLR) therapeutic product candidates, announced that it has dosed its first subject in a phase I study of its novel, orally-available TLR Therapeutic drug candidate for the treatment of systemic lupus erythematosus (SLE)...
Tuesday Oct 23, 2007
Experts Fret About How to Regulate "Generic" Biologics
Biopharmaceuticals are beginning to come off patent, promising cost savings for patients and headaches for regulators...
Tuesday Jun 26, 2007
Cytos Reports Results From Phase I/IIa Study With Vaccine Candidate CYT007-TNFQb for Treatment of Psoriasis; Demonstrated Safety and Tolerability but Transient Efficacy
Cytos Biotechnology AG, a public biotechnology company that specializes in the discovery, development, and commercialization of a new class of biopharmaceutical products called Immunodrugsâ„¢ reported results from a multicenter, randomized, placebo-controlled, and double-blind combined phase I/IIa study with CYT007-TNFQb, a novel therapeutic vaccine candidate for the treatment of psoriasis and other inflammatory conditions including rheumatoid arthritis (RA)...
Tuesday Feb 06, 2007
New RA Vaccine Targets Regulatory T-Cells
A pilot clinical trial of a new RA vaccine derived from autologous synovial T-cells shows proof-of-principle that inducing CD4+ regulatory T-cells can improve clinical and laboratory parameters in RA patients...
Monday Nov 27, 2006
Rituximab in RA
Rituximab prevents joint damage, can be given repeatedly, and does not block response to influenza vaccine in RA patients... Presented at ACR 2006 Meeting.
Tuesday Nov 14, 2006
PROMPT Study Shows "Window of Opportunity" in Early Undifferentiated Arthritis
Early MTX treatment can delay and possibly prevent progression to RA among anti-CCP positive patients who have early, undifferentiated arthritis... van Dongen H, et al. Presented at: ACR 2006 Meeting.
Monday Nov 13, 2006
Rheumatologists Urged to Remember Global Health Concerns
Rheumatologists must pay attention to the current global health crisis and aid in the efforts to bring life-saving tools to the developing world, urged Tadataka Yamada, MD, executive director of the Bill and Melinda Gates Foundation's Global Health Program in Seattle, WA... Presented at: ACR 2006 Meeting.
Monday Jan 30, 2006
PharmaFrontiers Obtains Exclusive License to T-Cell Vaccine for RA
PharmaFrontiers Corp, of The Woodlands, Texas, announced that it has acquired an exclusive worldwide license...
Thursday Jun 30, 2005
Debiopharm and Neovacs to Develop Anti-TNF-Alpha Therapeutic Vaccine
Debiopharm SA, a Swiss drug development company, and Neovacs SA, a French biotechnology company specializing in anticytokine immunogens, announced the execution of a license and equity agreement for the development of Neovacs' tumor necrosis factor-alpha (TNF-α) kinoidR, a nontoxic immunogenic cytokine derivative that, in the presence of a T-helper carrier protein, triggers an active human polyclonal antibody immune response against TNF-α, while avoiding the generation of anti-idiotypic antibodies (antibody resistance).
Wednesday Jun 29, 2005
The Immune Response Corporation Identifies Reduced FOXP3 Levels in MS Patients
An ongoing clinical trial conducted by The Immune Response Corporation (IRC) of Carlsbad, California, and Oregon Health & Science University (OHSU) in Portland has demonstrated that the investigational T-cell receptor (TCR) peptide vaccine NeuroVaxTM significantly increases levels of FOXP3, a transcription factor necessary for regulatory T-cell (Treg cells) development.
Wednesday Oct 20, 2004
Studies Show Potential of New Agents Targeting Beta-Cell Depletion
A Phase I trial of rituximab, and an initial clinical study of epratuzumab, showed the treatments to be well tolerated and linked to promising responses in lupus patients... Albert D et al. Presented at: Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Texas.
Wednesday Jul 14, 2004
Mycobacterial Vaccine Less Effective than Immunotherapies in Treatment of PSA
|
